{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:28:19Z","timestamp":1783164499552,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40123-023-00768-z","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:01:46Z","timestamp":1689940906000},"page":"2323-2346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-4067","authenticated-orcid":false,"given":"Praveen J.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6608-4256","authenticated-orcid":false,"given":"Pablo","family":"Villavicencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-8460","authenticated-orcid":false,"given":"Daren","family":"Hanumunthadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"1","key":"768_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37(1):6\u201316.","journal-title":"Eye (Lond)"},{"issue":"12","key":"768_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"1","key":"768_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146\u201352.","journal-title":"Ophthalmology"},{"issue":"4","key":"768_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1(4):314\u201321.","journal-title":"Ophthalmol Retina"},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2013a phase\u00a0IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"768_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57\u201365.","journal-title":"Ophthalmology"},{"issue":"5","key":"768_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126(5):723\u201334.","journal-title":"Ophthalmology"},{"issue":"3","key":"768_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37(3):1173\u201387.","journal-title":"Adv Ther"},{"issue":"3","key":"768_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","volume":"138","author":"PJ Kertes","year":"2020","unstructured":"Kertes PJ, Galic IJ, Greve M, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol. 2020;138(3):244\u201350.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"768_CR10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021;41(9):1911\u201320.","journal-title":"Retina"},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"852519","DOI":"10.3389\/fmed.2022.852519","volume":"9","author":"H Jia","year":"2022","unstructured":"Jia H, Lu B, Yuan Y, et al. A randomized, controlled trial of treat-and-extend vs. pro re nata regimen for neovascular age-related macular degeneration. Front Med (Lausanne). 2022;9:852519.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"768_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"10326","key":"768_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"1","key":"768_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40123-015-0031-5","volume":"4","author":"M Karampelas","year":"2015","unstructured":"Karampelas M, Pefkianaki M, Rees A, et al. Missed hospital appointments of patients receiving ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmol Ther. 2015;4(1):43\u20139.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"768_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721\u201331.","journal-title":"Eye (Lond)"},{"issue":"10","key":"768_CR16","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1167\/iovs.08-1935","volume":"49","author":"PJ Patel","year":"2008","unstructured":"Patel PJ, Chen FK, Rubin GS, Tufail A. Intersession repeatability of visual acuity scores in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(10):4347\u201352.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"768_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12886-019-1251-6","volume":"20","author":"G Staurenghi","year":"2020","unstructured":"Staurenghi G, Garweg JG, Gerendas BS, et al. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration\u2014results from the randomized, phase\u00a0IIIb OCTAVE study. BMC Ophthalmol. 2020;20(1):18.","journal-title":"BMC Ophthalmol"},{"key":"768_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02349-z","author":"E Preston","year":"2022","unstructured":"Preston E, Hamilton RD, Mahroo OA. Exploring regression to the mean in visual acuities by investigating measurements at two consecutive time points in untreated fellow eyes. Eye (Lond). 2022. https:\/\/doi.org\/10.1038\/s41433-022-02349-z.","journal-title":"Eye (Lond)"},{"issue":"3","key":"768_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1167\/iovs.07-1203","volume":"49","author":"PJ Patel","year":"2008","unstructured":"Patel PJ, Chen FK, Ikeji F, et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(3):1084\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"768_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/bjophthalmol-2016-308999","volume":"101","author":"D Hanumunthadu","year":"2017","unstructured":"Hanumunthadu D, Ilginis T, Restori M, et al. Repeatability of swept-source optical coherence tomography retinal and choroidal thickness measurements in neovascular age-related macular degeneration. Br J Ophthalmol. 2017;101(5):603\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"768_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138(10):1043\u201351.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"768_CR22","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond). 2021;35(11):2983\u201390.","journal-title":"Eye (Lond)"},{"key":"768_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02360-4","author":"RLW Hanson","year":"2022","unstructured":"Hanson RLW, Airody A, Sivaprasad S, Gale RP. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye (Lond). 2022. https:\/\/doi.org\/10.1038\/s41433-022-02360-4.","journal-title":"Eye (Lond)"},{"issue":"2","key":"768_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.oret.2019.09.006","volume":"4","author":"Y Patel","year":"2020","unstructured":"Patel Y, Miller DM, Fung AE, Hill LF, Rosenfeld PJ. Are dilated fundus examinations needed for OCT-guided retreatment of exudative age-related macular degeneration? Ophthalmol Retina. 2020;4(2):141\u20137.","journal-title":"Ophthalmol Retina"},{"issue":"14","key":"768_CR25","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1167\/iovs.16-19741","volume":"57","author":"M Lindner","year":"2016","unstructured":"Lindner M, Fang PP, Steinberg JS, et al. OCT angiography-based detection and quantification of the neovascular network in exudative AMD. Invest Ophthalmol Vis Sci. 2016;57(14):6342\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"768_CR26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"key":"768_CR27","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2147\/OPTH.S377262","volume":"16","author":"A Pucchio","year":"2022","unstructured":"Pucchio A, Krance SH, Pur DR, Miranda RN, Felfeli T. Artificial intelligence analysis of biofluid markers in age-related macular degeneration: a systematic review. Clin Ophthalmol. 2022;16:2463\u201376.","journal-title":"Clin Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00768-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:47:20Z","timestamp":1692614840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00768-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00768-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}